The future of asthma management: scientific questions that need to be addressed

How are acute and chronic oral corticosteroids managed once biologics are initiated in a real-life setting?
How should a second-line biological treatment be chosen if a patient fails with first-line respiratory biological therapy?
What are the different sub-phenotypes of non-eosinophilic asthma?
Can the natural course of the disease be modified by early intervention with anti-interleukin-5?
What is the effect of biological therapies on airway remodelling?
Could there be a beneficial impact of biologics on the cost of treatment through home care delivery in the severe asthma population?
What real-life factors could be used to distinguish between high and low responders to biologics?
What is the effect of using biologics in an acute asthma setting?